Background For postmenopausal women with hormone-receptor–positive breast cancer, the
most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear …

Background Aromatase inhibitors are associated with consistent improvements in disease-
free survival but not in overall survival. We conducted a literature-based meta-analysis of …

Background The effect of extended adjuvant aromatase inhibition in hormone receptor-
positive breast cancer after sequential endocrine therapy of tamoxifen followed by an …

Background Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or
after tamoxifen therapy is the treatment of choice for hormone-receptor–positive early breast …

BACKGROUND: A systematic review was undertaken to review the evidence for the use of
third-generation aromatase inhibitors (anastrozole, letrozole and exemestane) as adjuvant …

Background Clinical trial data have shown that among breast cancer patients who were
disease free after 5 years of adjuvant treatment with tamoxifen, further extended treatment …

Background Tamoxifen has been the standard adjuvant treatment for postmenopausal
women with hormone-responsive early breast cancer for more than 20 years. However, the …

Background: Aromatase inhibitors are considered standard adjuvant endocrine treatment of
postmenopausal women with hormone receptor-positive breast cancer, but it remains …

Background Uncertainty exists about the optimal schedule of adjuvant treatment of breast
cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the …

Hormone receptor-positive cancers are the most common tumor subtype among
postmenopausal women with breast cancer. Despite substantial improvements in disease …